A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough (2024)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.jacc.2024.09.019
- Subjects: ANTIMETABÓLITOS; COLESTEROL; LIPOPROTEÍNAS LDL; DISLIPIDEMIAS
- Agências de fomento:
- Financiamento CNPq
- Financiamento NIH
- Financiamento PCORI
- Financiamento Novartis Biociencias S.A.
- Financiamento Esperion Therapeutics, Inc.
- Financiamento Amgen
- Financiamento Arrowhead Pharmaceuticals, Inc.
- Financiamento Boehringer Ingelheim
- Financiamento 89Bio Inc.
- Financiamento Ionis
- Financiamento MSD
- Financiamento NewAmsterdam
- Financiamento Eli Lilly and Company Foundation
- Financiamento Cleerly
- Language: Inglês
- Imprenta:
- Source:
- Título: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ISSN: 0735-1097
- Volume/Número/Paginação/Ano: v. 84, n. 20, p. 2048-2050, 2024
- Este artigo NÃO possui versão em acesso aberto
-
Status: Nenhuma versão em acesso aberto identificada -
ABNT
SANTOS FILHO, Raul Dias dos e NASIR, Khurram e SHAPIRO, Michael David. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. NEW YORK: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/81896. Acesso em: 11 mar. 2026. , 2024 -
APA
Santos Filho, R. D. dos, Nasir, K., & Shapiro, M. D. (2024). A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. NEW YORK: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jacc.2024.09.019 -
NLM
Santos Filho RD dos, Nasir K, Shapiro MD. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough [Internet]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024 ; 84( 20): 2048-2050.[citado 2026 mar. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/81896 -
Vancouver
Santos Filho RD dos, Nasir K, Shapiro MD. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough [Internet]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024 ; 84( 20): 2048-2050.[citado 2026 mar. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/81896 - Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
- The Role of Statins in Current Guidelines
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
